| Outcome Measures: |
Primary: Resolution of pain: time to 50% reduction and complete resolution of pain in self-assessed pain intensity in the joint most affected., VAS (0-100mm) and 5-point Likert scale., Baseline (Day 1) to Day 7 | Secondary: Participant reported outcome measure of treatment response, 5-point Likert scale score, Day 2, Day 3, Day 4, Day 5, Day 6 and Day 7|Physician / Investigator assessment of joint tenderness and swelling, 4-point Likert scale score, Day 1, Day 2, Day 4 and Day 7|Participant assessment of activity limitation, Lower Extremity Functional Scale score, Day 1, Day 2, Day 5, Day 7|Participant assessment of activity limitation and quality of life, EQ-5D-5L health states will be used to calculate the index. Health profiles will be obtained and Quality Adjusted Life Years will be derived, Day 1, Day 2, Day 4, Day 7 and 8 weeks|Participant assessment of activity limitation and quality of life using HAQ-DI, Scores calculated from single scales and each dimension, Day 1, Day 7 and 8|Participant assessment of quality of life, SF-36 score, Day 1, Day 7 and 8|Healthcare resource use, Highly modified client service use inventory score, 8 weeks|CRP, Changes in CRP, Day 1, Day 4 and Day 7|White Cell Count, Changes in white cell count. Number of participants who develop neutropenia, Day 1, Day 4 and Day 7|eGFR, Changes in eGFR, Day 1, Day 4 and Day 7|Safety reporting, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Day 1 to 8 weeks
|
